ID   YST-1
AC   CVCL_5192
DR   CLO; CLO_0050136
DR   BioSample; SAMN03472012
DR   RCB; RCB2136
DR   TKG; TKG 0454
DR   Wikidata; Q54995528
RX   PubMed=1980563;
RX   PubMed=9290701;
RX   PubMed=16510576;
RX   PubMed=28556483;
CC   Population: Japanese.
CC   Doubling time: ~40 hours (PubMed=1980563).
CC   Derived from sampling site: Arm; hypodermis. Cell type=Schwann cell.
ST   Source(s): PubMed=28556483; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,12
ST   D16S539: 10,12
ST   D18S51: 13
ST   D19S433: 13,14
ST   D21S11: 29,31
ST   D2S1338: 18,19
ST   D3S1358: 16,18
ST   D5S818: 10,11
ST   D7S820: 9,10
ST   D8S1179: 10,15
ST   FGA: 19,24
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C3269; Schwannoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   8Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 16-12-21; Version: 15
//
RX   PubMed=1980563; DOI=10.1007/BF02899420;
RA   Nagashima Y., Ohaki Y., Tanaka Y., Sumino K., Funabiki T., Okuyama T.,
RA   Watanabe S.-I., Umeda M., Misugi K.;
RT   "Establishment of an epithelioid malignant schwannoma cell line (YST-1).";
RL   Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 59:321-327(1990).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=16510576; DOI=10.1158/0008-5472.CAN-05-3330;
RA   Miller S.J., Rangwala F., Williams J., Ackerman P., Kong S.,
RA   Jegga A.G., Kaiser S., Aronow B.J., Frahm S., Kluwe L., Mautner V.-F.,
RA   Upadhyaya M., Muir D., Wallace M.R., Hagen J., Quelle D.E., Watson M.A.,
RA   Perry A., Gutmann D.H., Ratner N.;
RT   "Large-scale molecular comparison of human Schwann cells to malignant
RT   peripheral nerve sheath tumor cell lines and tissues.";
RL   Cancer Res. 66:2584-2591(2006).
//
RX   PubMed=28556483; DOI=10.1002/1878-0261.12086;
RA   Kolberg M., Bruun J., Murumagi A., Mpindi J.P., Bergsland C.H.,
RA   Holand M., Eilertsen I.A., Danielsen S.A., Kallioniemi O.-P.,
RA   Lothe R.A.;
RT   "Drug sensitivity and resistance testing identifies PLK1 inhibitors
RT   and gemcitabine as potent drugs for malignant peripheral nerve sheath
RT   tumors.";
RL   Mol. Oncol. 11:1156-1171(2017).
//